




**DIRECTORATE GENERAL OF DRUG ADMINISTRATION**  
**MINISTRY OF HEALTH AND FAMILY WELFARE, BANGLADESH**

*Authorized Personnel Only*

**Annexure – 14**

|   |   |                           |                        |   |                  |   |
|---|---|---------------------------|------------------------|---|------------------|---|
|  | <b>FORM Title: Application Assessment Checklist for ICH CTD Dossier Module 3 (Testing Part)</b> |                           |                        |   |                  |  |
| Form No.<br>NRA-MA-013/F14-01   | Version No.<br>01   | Effective Date<br>JUN' 22 | Review Date<br>JUN' 27 | Authorized by<br> | Date<br>29.05.22 | Page No.<br>1 of 3  |

**APPLICATION ASSESSMENT CHECKLIST (ICH CTD – UPA AND IPA)**

This Application Assessment Checklist should be used to ensure the submission of a complete dataset for Module – 3 (Testing Part) in the ICH Common Technical Dossier (ICH CTD) format and assessment report of Module – 3 for UPA and IPA applications only. Colour scanned copies of the original documents should be submitted and original hard copies of documents are not required.

However, DGDA reserves the rights to request for the original or certified true copy of submitted documents if there is any doubt that a submitted scanned document is not an accurate reflection of the original document. The acceptance of the application after screening including assessment does not preclude requests by DGDA for additional documents or changes to the information/documents during evaluation. This Checklist should be completed by checking each item against the dossier according to the application type.

**Note:**

- Cells with  indicate that the documents shown are mandatory for the selected application type and evaluation route.
- Cells without  indicate that the documents shown are not required for the selected application type and evaluation route.


**Legend:**

|                  |     |                                  |
|------------------|-----|----------------------------------|
| Application type | UPA | Unintroduced Product Application |
|                  | IPA | Introduced Product Application   |
|                  | IND | Indigenous or locally developed  |
|                  | IMP | Imported                         |
|                  | RT  | Routine MA pathway               |
|                  | EUA | Emergency Use Authorization      |

Product Name:

Application Date:

10 NOV 2021





**DIRECTORATE GENERAL OF DRUG ADMINISTRATION  
MINISTRY OF HEALTH AND FAMILY WELFARE, BANGLADESH**

*Authorized Personnel Only*

**Annexure – 14**

**FORM Title: Application Assessment Checklist for ICH CTD Dossier Module 3 (Testing Part)**

|   |                   |                    |                       |                    |   |             |                 |
|---|-------------------|--------------------|-----------------------|--------------------|---|-------------|-----------------|
|  | <b>Form No.</b>   | <b>Version No.</b> | <b>Effective Date</b> | <b>Review Date</b> | <b>Authorized by</b>  | <b>Date</b> | <b>Page No.</b> |
|   | NRA-MA-013/F14-01 | 01                 | JUN' 22               | JUN' 27            |  | 29.05.22    | 2 of 3          |

**Module 3 – Laboratory Testing Part**

**Assessment Started on:**

| Section | Documents                                      | Submitted By<br>(Sign & Seal) | Application Type & Evaluation Route |     |           |     |     | DGDA Screening |                   |    | DGDA Assessment | Assessment Outcome |    |  |
|---------|--|-------------------------------|-------------------------------------|-----|-----------|-----|-----|----------------|-------------------|----|-----------------|--------------------|----|--|
|         |  |                               | UPA<br>RT                           | EUA | IPA<br>RT | EUA | IND | IMP            | Submitted?<br>Yes | No |                 |                    | NA |  |
| 3.2.P.4 | Control of inactive pharmaceutical ingredients |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.4.1 Specifications                       |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.4.2 Analytical procedures                |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.4.3 Validation of analytical procedures  |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.4.4 Justifications for specifications    |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.4.5 Novel excipients                     |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
| 3.2.P.5 | Control of pharmaceutical products             |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.5.1 Specifications                       |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.5.2 Analytical procedures                |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.5.3 Validation of analytical procedures  |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.5.4 Batch analysis                       |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.5.5 Characterization of impurities       |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
|         | 3.2.P.5.6 Justifications for specifications    |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |
| 3.2.P.6 | Reference standards or materials               |                               |                                     |     |           |     |     |                |                   |    |                 |                    |    |  |

Issue date: 10 NOV 2021

**ORIGINAL COPY**

Issued by





**DIRECTORATE GENERAL OF DRUG ADMINISTRATION  
MINISTRY OF HEALTH AND FAMILY WELFARE, BANGLADESH**

*Authorized Personnel Only*

**Annexure – 14**

**FORM Title: Application Assessment Checklist for ICH CTD Dossier Module 3 (Testing Part)**

|   |                   |                    |                       |                    |   |             |                 |
|---|-------------------|--------------------|-----------------------|--------------------|---|-------------|-----------------|
|  | <b>Form No.</b>   | <b>Version No.</b> | <b>Effective Date</b> | <b>Review Date</b> | <b>Authorized by</b>  | <b>Date</b> | <b>Page No.</b> |
|   | NRA-MA-013/F14-01 | 01                 | JUN' 22               | JUN' 27            |  | 29.05.22    | 3 of 3          |

| Section  | Documents                        | Submitted By<br>(Sign & Seal) | Application Type & Evaluation Route |   |                          |                          | DGDA Screening           |                          |                          | DGDA Assessment | Assessment Outcome |  |
|--|----------------------------------|-------------------------------|-------------------------------------|---|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-----------------|--------------------|--|
|  |                                  |                               | UPA                                 | IPA   | IND                      | IMP                      | Yes                      | No                       | NA                       |                 |                    |  |
| 3.2.P.7<br>Stability                             | Stability summary and conclusion |                               | <input type="checkbox"/>            | <input type="checkbox"/>                                  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |                 |                    |  |
|  |                                  |                               | 3.2.P.8.1                           | Stability summary and conclusion                          |                          |                          |                          |                          |                          |                 |                    |  |
|  |                                  |                               | 3.2.P.8.2                           | Post-approval stability protocol and stability commitment |                          |                          |                          |                          |                          |                 |                    |  |
|  | 3.2.P.8.3                        | Stability data                |                                     |   |                          |                          |                          |                          |                          |                 |                    |  |
| <b>Assessment Completed on</b>                   |                                  |                               |                                     |   |                          |                          |                          |                          |                          |                 |                    |  |
| <b>Assessment Summary</b>                        |                                  |                               |                                     |   |                          |                          |                          |                          |                          |                 |                    |  |
| <b>Recommendation</b>                            |                                  |                               |                                     |   |                          |                          |                          |                          |                          |                 |                    |  |
| <b>Head of Vaccine &amp; Biologics Sign/Date</b> |                                  |                               |                                     |   |                          |                          |                          |                          |                          |                 |                    |  |

Note: 1. Estimated Time duration for Dossier assessment is 05 Months through Routine MA pathway.  
2. Estimated Time duration for Dossier assessment is 05 days through EUA pathway.



Issue date: 10 NOV 2022

**CONTROLLED COPY**  
MINISTRY OF HEALTH AND FAMILY WELFARE  
BANGLADESH